Pay vs Performance Disclosure - USD ($)
|
12 Months Ended |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
| Pay vs Performance Disclosure |
|
|
|
|
|
| Pay vs Performance Disclosure, Table |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Value of Initial Fixed $100 | | | | | | | | | | | | | | | | | | | | | Investment Based On: | | | | | | | | | | | | | | | | | | | | | | | | Peer Group | | | | | | | | | | | | | | | Average | | | | | | | | Total | | | | | | | | | | | | | Summary | | Average | | | | | Stockholder | | | | | | | Summary | | | | | Compensation | | Compensation | | | | | Return | | | | | | | | | Compensation | | Compensation | | Table Total | | Actually Paid | | Total | | (Nasdaq | | | | | | | | | Table Total | | Actually Paid | | for Non-PEO | | to Non-PEO | | Stockholder | | Biotechnology | | Net Income | | Total Revenue | Year | | for PEO(1) | | to PEO(2) | | NEOs(3) | | NEOs(4) | | Return(5) | | Index)(6) | | (in thousands)(7) | | (in thousands)(8) | 2025 | | $ | 14,957,319 | | $ | 60,786,055 | | $ | 6,790,799 | | $ | 30,070,870 | | $ | 230.19 | | $ | 124.75 | | $ | (208,160) | | $ | 2,306,113 | 2024 | | $ | 13,032,674 | | $ | 95,390,804 | | $ | 6,124,794 | | $ | 46,461,399 | | $ | 159.06 | | $ | 93.49 | | $ | (190,426) | | $ | 1,696,911 | 2023 | | $ | 12,727,887 | | $ | 32,772,214 | | $ | 4,882,630 | | $ | 12,994,682 | | $ | 62.94 | | $ | 94.03 | | $ | (434,801) | | $ | 1,082,571 | 2022 | | $ | 8,246,281 | | $ | (10,478,887) | | $ | 4,548,786 | | $ | (4,682,784) | | $ | 40.36 | | $ | 89.90 | | $ | (547,799) | | $ | 820,222 | 2021 | | $ | 23,343,147 | | $ | 17,842,930 | | $ | 8,415,636 | | $ | 7,334,133 | | $ | 93.84 | | $ | 100.02 | | $ | (471,716) | | $ | 625,486 |
(1) | Our PEO for each year reported is Steven Chapman, our Chief Executive Officer. The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Chapman in the “Total” column of the Summary Compensation Table in the applicable fiscal year. |
(2) | In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid to our PEO during fiscal years 2025 and 2024, which consisted solely of adjustments to the PEO’s equity awards: |
| | | | | | | | | | | | | | | Description of Adjustment | | 2025 | | | 2024 | | | | | Summary Compensation Table – Total Compensation | | $ | 14,957,319 | | | | $ | 13,032,674 | | | | | | | - grant date fair value of option awards and stock awards granted in the covered fiscal year | | $ | (12,979,558) | | | | $ | (11,284,474) | | | | | | | + fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year | | $ | 25,210,438 | | | | $ | 40,945,878 | | | | | | | + change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years | | $ | 29,506,263 | | | | $ | 44,724,070 | | | | | | | + fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year | | $ | 0 | | | | $ | 833,838 | | | | | | | + change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year | | $ | 4,091,593 | | | | $ | 7,138,818 | | | | | | | - fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year | | $ | 0 | | | | $ | 0 | | | | | | | + dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation | | $ | 0 | | | | $ | 0 | | | | | | | Total Equity Adjustments (subtotal)* | | $ | 45,828,736 | | | | $ | 82,358,130 | | | | | | | Compensation Actually Paid | | $ | 60,786,055 | | | | $ | 95,390,804 | | | | | | |
(3) | The non-PEO NEOs for each year reported are as follows: |
For 2025: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz For 2024: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz For 2023: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz For 2022: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz For 2021: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz The dollar amounts reported in this column represent the average of the amounts reported for the non-PEO NEOs in the “Total” column of the Summary Compensation Table in the applicable fiscal year. (4) | In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid on average to our non-PEO NEOs during fiscal years 2025 and 2024, which consisted solely of adjustments to the non-PEO NEOs’ equity awards: |
| | | | | | | | | | | | | | | Description of Adjustment | | 2025 | | | 2024 | | | | | Summary Compensation Table – Total Compensation | | $ | 6,790,799 | | | | $ | 6,124,794 | | | | | | | - grant date fair value of option awards and stock awards granted in the covered fiscal year | | $ | (5,892,939) | | | | $ | (5,334,407) | | | | | | | + fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year | | $ | 11,445,966 | | | | $ | 19,355,974 | | | | | | | + change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years | | $ | 16,134,010 | | | | $ | 23,293,949 | | | | | | | + fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year | | $ | 0 | | | | $ | 383,798 | | | | | | | + change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year | | $ | 1,593,034 | | | | $ | 2,637,291 | | | | | | | - fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year | | $ | 0 | | | | $ | 0 | | | | | | | + dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation | | $ | 0 | | | | $ | 0 | | | | | | | Total Equity Adjustments (subtotal)* | | $ | 23,280,071 | | | | $ | 40,336,605 | | | | | | | Compensation Actually Paid | | $ | 30,070,870 | | | | $ | 46,461,399 | | | | | | |
(5) | Cumulative total stockholder return on our shares of common stock from December 31, 2020 through December 31, 2021, December 31, 2022, December 31, 2023, December 31, 2024, and December 31, 2025, respectively. Assumes the investment of $100 on December 31, 2020 in our shares of common stock and assumes the reinvestment of dividends, if any, although dividends have never been declared on our shares of common stock. |
(6) | Cumulative total stockholder return on the NASDAQ Biotechnology Index from December 31, 2020 through December 31, 2021, December 31, 2022, December 31, 2023, December 31, 2024, and December 31, 2025, respectively. Assumes the investment of $100 on December 31, 2020 in the NASDAQ Biotechnology Index and assumes the reinvestment of dividends. |
(7) | The dollar amounts reported represent the amount of net income reflected in our audited financial statements for the applicable year. |
(8) | The dollar amounts reported represent the amount of total revenue reflected in our audited financial statements for the applicable year. |
|
|
|
|
|
| Company Selected Measure Name |
Total Revenue
|
|
|
|
|
| Named Executive Officers, Footnote |
(1) | Our PEO for each year reported is Steven Chapman, our Chief Executive Officer. The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Chapman in the “Total” column of the Summary Compensation Table in the applicable fiscal year. |
(3) | The non-PEO NEOs for each year reported are as follows: |
For 2025: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz For 2024: Michael Brophy, John Fesko, Solomon Moshkevich, and Matthew Rabinowitz For 2023: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz For 2022: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz For 2021: Michael Brophy, Robert Schueren, Daniel Rabinowitz, and Matthew Rabinowitz The dollar amounts reported in this column represent the average of the amounts reported for the non-PEO NEOs in the “Total” column of the Summary Compensation Table in the applicable fiscal year.
|
|
|
|
|
| Peer Group Issuers, Footnote |
(6) | Cumulative total stockholder return on the NASDAQ Biotechnology Index from December 31, 2020 through December 31, 2021, December 31, 2022, December 31, 2023, December 31, 2024, and December 31, 2025, respectively. Assumes the investment of $100 on December 31, 2020 in the NASDAQ Biotechnology Index and assumes the reinvestment of dividends. |
|
|
|
|
|
| PEO Total Compensation Amount |
$ 14,957,319
|
$ 13,032,674
|
$ 12,727,887
|
$ 8,246,281
|
$ 23,343,147
|
| PEO Actually Paid Compensation Amount |
$ 60,786,055
|
95,390,804
|
32,772,214
|
(10,478,887)
|
17,842,930
|
| Adjustment To PEO Compensation, Footnote |
(2) | In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid to our PEO during fiscal years 2025 and 2024, which consisted solely of adjustments to the PEO’s equity awards: |
| | | | | | | | | | | | | | | Description of Adjustment | | 2025 | | | 2024 | | | | | Summary Compensation Table – Total Compensation | | $ | 14,957,319 | | | | $ | 13,032,674 | | | | | | | - grant date fair value of option awards and stock awards granted in the covered fiscal year | | $ | (12,979,558) | | | | $ | (11,284,474) | | | | | | | + fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year | | $ | 25,210,438 | | | | $ | 40,945,878 | | | | | | | + change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years | | $ | 29,506,263 | | | | $ | 44,724,070 | | | | | | | + fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year | | $ | 0 | | | | $ | 833,838 | | | | | | | + change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year | | $ | 4,091,593 | | | | $ | 7,138,818 | | | | | | | - fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year | | $ | 0 | | | | $ | 0 | | | | | | | + dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation | | $ | 0 | | | | $ | 0 | | | | | | | Total Equity Adjustments (subtotal)* | | $ | 45,828,736 | | | | $ | 82,358,130 | | | | | | | Compensation Actually Paid | | $ | 60,786,055 | | | | $ | 95,390,804 | | | | | | |
|
|
|
|
|
| Non-PEO NEO Average Total Compensation Amount |
$ 6,790,799
|
6,124,794
|
4,882,630
|
4,548,786
|
8,415,636
|
| Non-PEO NEO Average Compensation Actually Paid Amount |
$ 30,070,870
|
46,461,399
|
12,994,682
|
(4,682,784)
|
7,334,133
|
| Adjustment to Non-PEO NEO Compensation Footnote |
(4) | In accordance with SEC rules, the following adjustments were made to determine the compensation actually paid on average to our non-PEO NEOs during fiscal years 2025 and 2024, which consisted solely of adjustments to the non-PEO NEOs’ equity awards: |
| | | | | | | | | | | | | | | Description of Adjustment | | 2025 | | | 2024 | | | | | Summary Compensation Table – Total Compensation | | $ | 6,790,799 | | | | $ | 6,124,794 | | | | | | | - grant date fair value of option awards and stock awards granted in the covered fiscal year | | $ | (5,892,939) | | | | $ | (5,334,407) | | | | | | | + fair value at fiscal year end of outstanding and unvested option awards and stock awards granted in the covered fiscal year | | $ | 11,445,966 | | | | $ | 19,355,974 | | | | | | | + change in fair value of outstanding and unvested option awards and stock awards granted in prior fiscal years | | $ | 16,134,010 | | | | $ | 23,293,949 | | | | | | | + fair value on vesting date of option awards and stock awards granted in the covered fiscal year that vested during the covered fiscal year | | $ | 0 | | | | $ | 383,798 | | | | | | | + change in fair value as of the vesting date of option awards and stock awards granted in prior fiscal years that vested in the covered fiscal year | | $ | 1,593,034 | | | | $ | 2,637,291 | | | | | | | - fair value of as of prior fiscal year end of option awards and stock awards granted in prior fiscal years that failed to meet applicable vesting conditions during the covered fiscal year | | $ | 0 | | | | $ | 0 | | | | | | | + dollar value of dividends or earnings paid on option awards or stock awards in the covered fiscal year prior to vesting that are not otherwise included in total compensation | | $ | 0 | | | | $ | 0 | | | | | | | Total Equity Adjustments (subtotal)* | | $ | 23,280,071 | | | | $ | 40,336,605 | | | | | | | Compensation Actually Paid | | $ | 30,070,870 | | | | $ | 46,461,399 | | | | | | |
|
|
|
|
|
| Tabular List, Table |
Most Important Performance Measures For 2025, the most important performance measures used to inform our executive compensation decisions included the following:
|
|
|
|
|
| Total Shareholder Return Amount |
$ 230.19
|
159.06
|
62.94
|
40.36
|
93.84
|
| Peer Group Total Shareholder Return Amount |
124.75
|
93.49
|
94.03
|
89.9
|
100.02
|
| Net Income (Loss) |
$ (208,160,000)
|
$ (190,426,000)
|
$ (434,801,000)
|
$ (547,799,000)
|
$ (471,716,000)
|
| Company Selected Measure Amount |
2,306,113,000
|
1,696,911,000
|
1,082,571,000
|
820,222,000
|
625,486,000
|
| PEO Name |
Steven Chapman
|
|
|
|
|
| Measure:: 1 |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Name |
Total revenue
|
|
|
|
|
| Non-GAAP Measure Description |
(8) | The dollar amounts reported represent the amount of total revenue reflected in our audited financial statements for the applicable year. |
|
|
|
|
|
| Measure:: 2 |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Name |
Product gross margin
|
|
|
|
|
| Measure:: 3 |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Name |
Operating cash flow
|
|
|
|
|
| PEO | Equity Awards Adjustments |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
$ 45,828,736
|
$ 82,358,130
|
|
|
|
| PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
(12,979,558)
|
(11,284,474)
|
|
|
|
| PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
25,210,438
|
40,945,878
|
|
|
|
| PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
29,506,263
|
44,724,070
|
|
|
|
| PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
0
|
833,838
|
|
|
|
| PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
4,091,593
|
7,138,818
|
|
|
|
| PEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
0
|
0
|
|
|
|
| PEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
0
|
0
|
|
|
|
| Non-PEO NEO | Equity Awards Adjustments |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
23,280,071
|
40,336,605
|
|
|
|
| Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
(5,892,939)
|
(5,334,407)
|
|
|
|
| Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
11,445,966
|
19,355,974
|
|
|
|
| Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
16,134,010
|
23,293,949
|
|
|
|
| Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
0
|
383,798
|
|
|
|
| Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
1,593,034
|
2,637,291
|
|
|
|
| Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
0
|
0
|
|
|
|
| Non-PEO NEO | Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year |
|
|
|
|
|
| Pay vs Performance Disclosure |
|
|
|
|
|
| Adjustment to Compensation, Amount |
$ 0
|
$ 0
|
|
|
|